Inteum Company
Links
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Search Results - cancer+treatment
28
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
STING Agonist 8803 for Blood-Brain Barrier Opening in Glioblastoma Treatment
SHORT DESCRIPTION Chemical compound that opens the blood-brain barrier to enhance delivery of therapeutics for treating glioblastoma. INVENTORS Amy Heimberger* Northwestern University Feinberg School of Medicine, Department of Neurological Surgery * Principal Investigator NU 2025-212 IP...
Published: 4/29/2026
|
Updated: 4/27/2026
|
Inventor(s):
Keywords(s):
AD - Alzheimer’s Disease
,
Adjunct therapy
,
ALS - Amyotrophic Lateral Sclerosis
,
Animal Model
,
Autoimmune disease
,
Bladder cancer
,
Brain cancer
,
Breast cancer
,
Cancer Treatment
,
Cancer/Oncology
,
Cervical cancer
,
CNS - Central Nervous System
,
Colon cancer
,
Drug delivery
,
Endometrial cancer
,
Gastric cancer
,
GBM - Glioblastoma
,
Head and neck cancer
,
Immunology
,
Immunotherapy
,
Liver cancer
,
Lung cancer
,
MS - Multiple Sclerosis
,
Neurodegenerative disease
,
Neurologic disease
,
Ovarian cancer
,
Pancreatic cancer
,
PD - Parkinson's Disease
,
Prostate cancer
,
Repurposed Drugs
,
Research tool
,
Small molecule
,
Targeted therapy
,
TBI - Traumatic brain injury
,
Therapeutics
Category(s):
Life Sciences > Therapeutics
,
Life Sciences > Biomarkers & Biomedical Research Tools
Targeting EGFR Co-Amplified Long-Noncoding RNA for Glioblastoma Treatment
NU 2025-335 INVENTORS Shi-Yuan Cheng* Xiaozhou Yu Bo Hu Runxin Wu Xiao Song SHORT DESCRIPTION This invention provides compositions and methods for inhibiting ELDR and HELDR, two long non-coding RNAs (lncRNAs) that are frequently co-amplified in glioblastoma (GBM) with the epidermal growth factor receptor (EGFR) gene, and which drive tumorigenesis...
Published: 3/30/2026
|
Updated: 3/30/2026
|
Inventor(s):
Keywords(s):
Brain cancer
,
Cancer Treatment
,
Cancer/Oncology
,
Therapeutics
Category(s):
Life Sciences > Therapeutics
ICA‑1S and ζ‑Stat: Selective aPKC Inhibitors for Anti‑Angiogenic Control Neuroblastoma
Advantages Upstream pathway control: Suppresses VEGF‑A by targeting aPKC, a master regulator of angiogenic signaling. Selective, small-molecule mechanism: offers lower immunogenicity and easier development than antibody-based therapies. Combination-therapy ready: upstream angiogenic pathway control enables synergy with existing treatments. Summary Neuroblastoma...
Published: 5/4/2026
|
Updated: 2/16/2026
|
Inventor(s):
Sloan Breedy
,
Wishrawana Ratnayake
,
Mildred Acevedo-Duncan
Keywords(s):
Cancer Treatment
,
Small Molecules
Category(s):
Technology Classifications > Cancer
,
Technology Classifications > Chemistry
,
Technology Classifications > Medical > Oncology
,
Technology Classifications > Medical > Neuroscience
,
Technology Classifications > Medical > Therapeutics
,
Technology Classifications > Medical > Pharmaceuticals
Retinoic Acid Agonists for Attenuation of Doxorubicin-Induced Cardiotoxicity
SHORT DESCRIPTION A method for preventing cardiotoxicity in patients undergoing anthracycline-based chemotherapy using retinoic acid receptor gamma (RARG) agonists. INVENTORS Paul W Burridge*, PhD Associate Professor, Pharmacology, Northwestern University Feinberg School of Medicine * Principal Investigator NU...
Published: 2/6/2026
|
Updated: 2/6/2026
|
Inventor(s):
Keywords(s):
Cancer Treatment
,
Cancer/Oncology
,
Cardiology and Cardiovascular disease
,
Chemotherapy
,
Therapeutics
Category(s):
Life Sciences > Therapeutics
Electrospun Multilayered Nanofiber-Nanoparticle Membrane Drug Carrier
Advantages Delivers cancer drugs exactly where they’re needed, reducing harm to the rest of the body. Provides steady, long-lasting treatment, helping prevent tumor regrowth after surgery. Uses safe, biodegradable materials, eliminating the need for device removal or additional procedures. Designed for easy scaling, supporting future clinical...
Published: 5/4/2026
|
Updated: 12/8/2025
|
Inventor(s):
Ridita Khan
,
Sylvia Thomas
Keywords(s):
Biotechnology
,
Cancer Treatment
,
Drug Delivery and Nanomedicine
Category(s):
Technology Classifications > Medical > Medical Nanotechnology
,
Technology Classifications > Cancer
Novel Combination Treatment for Glioblastoma
Advantages: Temozolomide (TMZ), Cannabidiol (CBD), and CCR6/CCL20 inhibitors work together to overcome Glioblastoma resistance and enhance efficacy Targeted CCL20/CCR6 inhibition blocks survival pathways in glioblastoma, reducing resistance and relapse while improving outcomes Enhances CD8+ T cells and rewires immunity, offering powerful, lasting...
Published: 5/4/2026
|
Updated: 4/30/2025
|
Inventor(s):
Subhra Mohapatra
,
Shyam Mohapatra
,
Ryan Green
,
Karthick Mayilsamy
Keywords(s):
Cancer Treatment
,
Pharmaceuticals
Category(s):
Technology Classifications > Chemistry
,
Technology Classifications > Medical > Pharmaceuticals
,
Technology Classifications > Medical
Novel HPV Epitopes for Designing Cervical Cancer Immunotherapies
Advantages: Specific targeting of HPV epitopes from E2 and E6 proteins opens new avenues for cervical cancer immunotherapies. Correlation of high chemical complementarity scores between TCR CDR3 regions and HPV epitopes with improved overall and disease-free survival provides a reliable biomarker that complement traditional clinical factors. Whole...
Published: 5/4/2026
|
Updated: 4/24/2025
|
Inventor(s):
George Blanck
,
Deo Rei Agnila
,
Rahul Jain
,
Michael Diaz
,
Tabitha Hudock
,
Rachel Eakins
,
Andrea Chobrutskiy
,
Boris Chobrutskiy
Keywords(s):
Biomarker
,
Cancer Treatment
,
Women’s Health
Category(s):
Technology Classifications > Cancer > Cancer Diagnostics
,
Technology Classifications > Medical > Therapeutics
,
Technology Classifications > Medical > Womens Health
Multiphasic Localized in vivo Molecular Delivery
Advantages: Asymmetric biphasic pulses significantly reduced stimulation of skeletal muscle contractions in vivo and enhanced gene delivery Enables delivery of insulin and glucokinase to replace daily injections with long-term, non-immunogenic protein expression in skeletal muscle Higher-efficiency gene therapies avoid immunogenicity and off-target...
Published: 5/4/2026
|
Updated: 2/21/2025
|
Inventor(s):
Anna Bulysheva
,
Mark Jaroszeski
,
Richard Heller
Keywords(s):
Cancer Treatment
,
Drug Delivery Systems
,
Medical Therapeutics Gene Therapy
,
Wound and Tissue Healing
Category(s):
Technology Classifications > Medical > Medical Devices
,
Technology Classifications > Cancer
,
Technology Classifications > Medical > Biomedical Engineering
Colorectal Cancer Gene Expression Signature as a Predictor for Therapy Outcomes
Advantages: Novel biomarker development: Unique 10-gene signatures distinguish the contributions of tumor epithelium (EPI) & tumor microenvironment (TME) in colorectal cancer (CRC) Clinical Relevance: EPIS signature predicts better progression-free survival in cetuximab-treated metastatic CRC patients; TMES correlates with worse survival outcomes Enhanced...
Published: 5/4/2026
|
Updated: 2/12/2025
|
Inventor(s):
Timothy Yeatman
,
Mingli Yang
Keywords(s):
Cancer Treatment
,
Pharmaceuticals
Category(s):
Technology Classifications > Cancer
,
Technology Classifications > Medical
,
Technology Classifications > Chemistry
Drugs That Regulate Heparan Sulfate Expression for
Cancer Treatment
Advantages: Developed a novel assay for identifying repurposed drugs targeting HS-related gene expression Revealed a dose-dependent inhibition of the HS-related gene EXT1 with Vitamin D/ Calcitriol EXT1 stable cell line with luciferase reporter ensures specificity in identifying EXT1 regulators, minimizing off-target effects Summary: Heparan...
Published: 5/4/2026
|
Updated: 4/29/2024
|
Inventor(s):
Lianchun Wang
Keywords(s):
Biotechnology
,
Cancer Treatment
,
Medical Therapeutics Gene Therapy
Category(s):
Technology Classifications > Medical > Biotechnology
,
Technology Classifications > Medical > Therapeutics
,
Technology Classifications > Medical > Pharmaceuticals
1
2
3